

Identifying genetic determinants of outcome in multiple sclerosis

Submission date 22/04/2023	Recruitment status Not yet recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 04/05/2023	Overall study status Ongoing	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 19/06/2025	Condition category Nervous System Diseases	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Multiple sclerosis (MS) is what scientists call an “autoimmune” disease. In such diseases the immune system is faulty and mistakenly attacks part of the body. In MS, this faulty attack is directed against the central nervous system (CNS); that is against the brain and the spinal cord. The damage caused by MS results in increasingly severe neurological disability that is known as disease “progression”. The rate at which this irreversible damage develops varies greatly between patients. Some become markedly disabled very quickly, while others develop little or no disability even after years. This study will examine the DNA code from people with MS in order to identify genetic factors that influence how quickly progression develops in the disease. That is, to identify changes in the DNA sequence that influence the outcome of the disease.

Who can participate?

People with MS who have had their disability recorded at least once using a clinical assessment called the Extended Disability Status Scale (EDSS). The EDSS is frequently measured in MS research studies and is now also often measured as part of routine clinical care.

What does the study involve?

The study involves the genetic analysis of DNA donated by participants. The DNA will be extracted either from venous blood or saliva collected from participants. The analysis of the DNA will be undertaken in the laboratory. The genetic data emerging from the laboratory analysis will be correlated with the demographic and clinical details collected about the participants.

What are the possible benefits and risks of participating?

This is an observational study in which the only intervention is the collection of venous blood. This collection will be undertaken by professional appropriately trained staff. The collection of venous blood is a routine procedure with no meaningful risk. The study will also involve the sharing of data about participants between the researchers involved in the study. All data sharing in the study will be undertaken in accordance with best practice and legal requirements such as GDPR. There are no benefits to participants from taking part in the study other than the knowledge that they are helping to bring effective treatments closer for future generations of patients.

Where is the study run from?
The University of Cambridge (UK)

When is the study starting and how long is it expected to run for?
September 2022 to September 2030

Who is funding the study?
Funding for the study is not yet confirmed

Who is the main contact?
Prof. Stephen Sawcer, sjs1016@cam.ac.uk

Contact information

Type(s)

Principal Investigator

Contact name

Prof Stephen Sawcer

ORCID ID

<https://orcid.org/0000-0001-7685-0974>

Contact details

Department of Clinical Neurosciences
Addenbrookes Hospital, BOX165
Hills Road
Cambridge
United Kingdom
CB2 0QQ
+44 (0)1223 762040
sjs1016@cam.ac.uk

Type(s)

Scientific

Contact name

Prof Stephen Sawcer

Contact details

Department of Clinical Neurosciences
Addenbrookes Hospital, BOX165
Hills Road
Cambridge
United Kingdom
CB2 0QQ
+44 (0)1223 762040
sjs1016@cam.ac.uk

Type(s)

Public

Contact name

Prof Stephen Sawcer

Contact details

Department of Clinical Neurosciences
Addenbrookes Hospital, BOX165
Hills Road
Cambridge
United Kingdom
CB2 0QQ
+44 (0)1223 762040
sjs1016@cam.ac.uk

Additional identifiers

EudraCT/CTIS number

Nil known

IRAS number

324856

ClinicalTrials.gov number

Nil known

Secondary identifying numbers

A096498, IRAS 324856

Study information

Scientific Title

Progression in Multiple Sclerosis

Acronym

PIMS

Study objectives

The primary aim of this study is to identify genetic variants influencing the clinical course of multiple sclerosis

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Genome wide association screen

Primary study design

Observational

Secondary study design

Epidemiological study

Study setting(s)

Laboratory

Study type(s)

Other

Participant information sheet

Not available in web format, please use the contact details to request a participant information sheet

Health condition(s) or problem(s) studied

Multiple sclerosis

Interventions

The researchers will undertake array-based genome-wide genotyping in DNA extracted from patients' venous blood or saliva

Intervention Type

Genetic

Primary outcome measure

Disability measured using the Extended Disability Status Scale (EDSS) and age-corrected to generate the Age-Related Multiple Sclerosis Severity (ARMSS) Score. All available measures of the ARMSS will be considered in the analysis as observed at any timepoint in the disease course.

Secondary outcome measures

Time to event measures including time to EDSS 6.0 and time to confirmed disability worsening. These variables will be assessed in the sub-group of patients with EDSS measured at multiple timepoints.

Overall study start date

01/09/2022

Completion date

30/09/2030

Eligibility**Key inclusion criteria**

1. A locally confirmed diagnosis of multiple sclerosis
2. At least one measure of Extended Disability Severity Score (EDSS)
3. Able to give valid informed consent

Participant type(s)

Patient

Age group

Adult

Sex

Both

Target number of participants

10000

Key exclusion criteria

1. Patients with Radiologically or Clinically Isolated Syndrome (RIS or CIS)
2. Comorbidities causing significant disability likely to have confounded the reliability of the EDSS
3. Inclusion in the discovery cohort of the recently completed first progression GWAS

Date of first enrolment

01/10/2025

Date of final enrolment

30/09/2028

Locations

Countries of recruitment

England

United Kingdom

Study participating centre

Addenbrookes

Addenbrookes Hospital

Hills Road

Cambridge

United Kingdom

CB2 0QQ

Sponsor information

Organisation

Cambridge University Hospitals NHS Foundation Trust

Sponsor details

Addenbrookes Hospital
Hills Road
Cambridge
England
United Kingdom
CB2 0QQ
+44 (0)1223 348490
cuh.research@nhs.net

Sponsor type

Hospital/treatment centre

Website

<http://www.cuh.org.uk/>

ROR

<https://ror.org/04v54gj93>

Funder(s)

Funder type

Other

Funder Name

Not yet confirmed

Results and Publications

Publication and dissemination plan

Planned publication in a high-impact peer-reviewed journal

Intention to publish date

01/06/2026

Individual participant data (IPD) sharing plan

It is the researchers' intention to store the data generated in this study (demographic, clinical and genetic) in a genomics data repository such as the European Genome-Phenome Archive (EGA, <https://ega-archive.org/>). Anonymised data will be available when the results of the study are published by application to the Data Access Committee (DAC) via the repository. All participants will consent to data sharing with bona fide third-party researchers undertaking appropriate biomedical research.

IPD sharing plan summary

Stored in publicly available repository